Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.
MICs of clarithromycin and its major human metabolite, 14-hydroxy-clarithromycin, for Haemophilus influenzae in combination were reduced two- to fourfold compared with the MICs of each compound alone. Serum reduced the MICs of the parent compound and metabolite two- to fourfold compared with the MIC...
Gespeichert in:
| Veröffentlicht in: | Antimicrob Agents Chemother |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society for Microbiology (ASM)
1990
|
| Schlagworte: | |
| Online-Zugang: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC175991/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2143642/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.34.7.1407 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
